MYGN 외환 뉴스
Myriad Genetics Slashes FY22 Outlook As Q3 Results Miss Estimates; Stock Down 8%
While reporting financial results for the third quarter on Tuesday, genetic testing firm Myriad Genetics, Inc. (MYGN) slashed its earnings and adjusted earnings and revenue guidance for the full year 2022 to reflect third quarter business updates.
RTTNews
|
813 일 전
Myriad Genetics Trims FY22 Profit Outlook, But Q2 Results Top Estimates
While reporting financial results for the second quarter on Thursday, genetic testing firm Myriad Genetics, Inc. (MYGN) slashed its earnings and adjusted earnings guidance for the full year 2022, while maintaining annual revenue outlook.
RTTNews
|
902 일 전
